XML 33 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer,
revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
Revenue
 Year Ended December 31,
 20222021
Medicare39 %19 %
Medicare Advantage15 %13 %
Blue Shield*12 %
*Less than 10%.
Accounts Receivable
 December 31,
 20222021
Medicare21 %*
Medicare Advantage13 %*
Blue Shield*19 %
United Healthcare*18 %
*Less than 10%.
Disaggregation of Revenue
The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 Year Ended December 31,
 20222021
Revenue:
Commercial$18,975 $27,499 
Government17,687 9,221 
Client(1)7,928 9,288 
Other(2)973 1,091 
Janssen (SIMPONI®)
— 1,200 
Total revenue$45,563 $48,299 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay.
Schedule of Restricted Cash and Cash Equivalents
Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 December 31,
 20222021
Cash and cash equivalents$62,391 $99,442 
Restricted cash200 100 
$62,591 $99,542 
Schedule of Cash and Cash Equivalents
Cash, cash equivalents and restricted cash presented in the accompanying statements of cash flows consist of the following (in thousands):
 December 31,
 20222021
Cash and cash equivalents$62,391 $99,442 
Restricted cash200 100 
$62,591 $99,542 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares): 
 Years Ended December 31,
 20222021
Warrants to purchase common stock409,108 409,108 
Common stock options1,421,235 2,014,330 
Restricted stock units1,036,208 415,325 
Employee stock purchase plan58,711 20,193 
Total2,925,262 2,858,956